drugset / Trial / NCT04620187
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.
Timeline
- Start
- 2020-12-24
- Primary completion
- 2028-02-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ado-trastuzumab (T) emtansine | Unknown | 3.6 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 2 unknown | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |